CADL

Healthcare Biotechnology

Candel Therapeutics, Inc.

$9.87

-0.32 -3.14% today

Price History

Not enough data

Key Stats

Market Cap

723.18M

Avg Volume

1.24M

EPS

-$1.46

52W High

$14.00

52W Low

$4.35

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-15.79

P/B Ratio

5.96

EV/EBITDA

-8.85

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(81.8%)

Return on Assets

(28.6%)

Liquidity & Leverage

Current Ratio

16.09

Quick Ratio

15.89

Debt / Equity

0.39

Total Cash

201.56M

Total Debt

49.52M

About

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.